Related Experiment Video
Updated: Oct 15, 2025
04:29
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
28.9K
Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary
Jeong Seok Seo1, Won-Myong Bahk2, Young Sup Woo2
1Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, Korea.
Summary
The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) has been revised, showing a trend towards more aggressive treatment strategies for major depressive disorder (MDD) in Korea.
Area of Science:
- Neuropsychopharmacology
- Psychiatry
- Clinical Practice Guidelines
Background:
- The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) was first developed in 2002.
- Four revisions have been conducted since its inception.
- The project aims to guide the treatment of depressive disorders.
Purpose of the Study:
- To update treatment guidelines for major depressive disorder (MDD).
- To reflect current clinical practices in Korea.
- To compare findings with previous KMAP-DD iterations.
Main Methods:
- Maintained the overall structure of the previous questionnaire for consistency.
- Survey covered pharmacological strategies for MDD, persistent depressive disorder, treatment-resistant depression, safety/comorbidity considerations, special populations, and non-pharmacological therapies.
- Statistically derived first-, second-, and third-line treatment strategies.
Main Results:
- Limited changes due to lack of new drugs or strategies since 2017.
- Observed a trend towards more active and aggressive treatment in Korea.
- Increased preference for atypical antipsychotics (AAPs), particularly aripiprazole, and combination strategies with AAPs.
Conclusions:
- The KMAP-DD provides clinicians with practical information for treating MDD.
- It bridges the gap between clinical practice and evidence-based medicine.
- The updated guidelines reflect evolving treatment trends in Korea.
More Related Videos
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
257
04:33Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
869
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
429
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
429
01:25Antidepressant Drugs: Overview
884
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
884
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
743
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
743
01:28Drug Therapy
118
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
118
01:27Diagnostic and Statistical Manual of Mental Disorders (DSM)
290
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
290
01:18Depression: Overview
429
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
429